APA (7th ed.) Citation

Fleischmann, R. M., Bock, A. E., Zhang, W., Godfrey, C. M., Vranic, I., Cronenberger, C., & Dokoupilová, E. (2022). Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology & Therapy, 9(3), 839. https://doi.org/10.1007/s40744-022-00439-8

Chicago Style (17th ed.) Citation

Fleischmann, Roy M., Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger, and Eva Dokoupilová. "Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis." Rheumatology & Therapy 9, no. 3 (2022): 839. https://doi.org/10.1007/s40744-022-00439-8.

MLA (9th ed.) Citation

Fleischmann, Roy M., et al. "Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis." Rheumatology & Therapy, vol. 9, no. 3, 2022, p. 839, https://doi.org/10.1007/s40744-022-00439-8.